|
| 36756959 | Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial. | J Urol | 2023 |
| 37585665 | Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide? | Future Oncol | 2023 |
| 37930121 | Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. | Cancer Res Commun | 2023 |
| 37672815 | The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer. | Eur J Cancer | 2023 |
| 36952634 | Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. | J Clin Oncol | 2023 |
| 37022702 | Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 37399894 | Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. | Ann Oncol | 2023 |
| 36610815 | Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy. | Urol Oncol | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 34844839 | Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. | Eur J Cancer | 2022 |
| 35509235 | Clinical outcomes and patterns of population-based management of urachal carcinoma of the bladder: An analysis of the National Cancer Database. | Cancer Med | 2022 |
| 35440417 | Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. | Eur Urol | 2022 |
| 35379845 | MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. | Nat Commun | 2022 |
| 35703113 | A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an <i>in situ</i> vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial. | Future Oncol | 2022 |
| 35697807 | Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. | Nat Biotechnol | 2022 |
| 35450732 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. | Eur Urol | 2022 |
| 35385726 | Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. | Cell Rep | 2022 |
| 36226865 | Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide? | Future Oncol | 2022 |
| 35131040 | Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. | Lancet Oncol | 2022 |
| 35181268 | Association Between Perioperative Chemotherapy and Survival in Men Undergoing Radical Resection for Primary Urethral Urothelial Carcinoma: An Analysis of the National Cancer Database. | Clin Genitourin Cancer | 2022 |
| 32675015 | A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. | Clin Genitourin Cancer | 2021 |
| 33753455 | Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. | Clin Cancer Res | 2021 |
| 33771918 | Estrogen receptor β and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate. | Proc Natl Acad Sci U S A | 2021 |
| 34584218 | Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel. | Oncogene | 2021 |
| 34784577 | Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. | Eur J Cancer | 2021 |
| 34516499 | The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progression. | Medicine (Baltimore) | 2021 |
| 34600602 | Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. | Lancet Oncol | 2021 |
| 34536949 | Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. | Eur J Cancer | 2021 |
| 33208612 | Prostate Cancer Liver Metastases Presenting as Relatively Photopenic Lesions on 18F-Fluciclovine PET/CT. | Clin Nucl Med | 2021 |
| 31412017 | Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients. | Eur Urol Oncol | 2020 |
| 32001144 | Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. | Eur Urol | 2020 |
| 31787484 | Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database. | Eur J Cancer | 2020 |
| 31864524 | Epigenetics and prostate cancer: defining the timing of DNA methyltransferase deregulation during prostate cancer progression. | Pathology | 2020 |
| 31986451 | A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. | Eur J Cancer | 2020 |
| 31941830 | A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. | Clin Cancer Res | 2020 |
| 33339136 | Neuroendocrine and Aggressive-Variant Prostate Cancer. | Cancers (Basel) | 2020 |
| 32605716 | Corrigendum to "Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database" [Eur J Canc 125, (January 2020) 153-163]. | Eur J Cancer | 2020 |
| 32576626 | The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. | Clin Cancer Res | 2020 |
| 32723589 | Erratum to 'Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration-resistant prostate cancer: The CATS international database' [European Journal of Cancer, Volume 125 (January 2020) Pages 153-163]. | Eur J Cancer | 2020 |
| 33010985 | Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring. | Eur Urol | 2020 |
| 32469184 | Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. | N Engl J Med | 2020 |
| 32543237 | An evaluation of apalutamide for the treatment of prostate cancer. | Expert Opin Pharmacother | 2020 |
| 27141017 | Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. | Ann Oncol | 2019 |
| 31300238 | Prostate Cancer: Quo Vadis? | Eur Urol | 2019 |
| 31176622 | Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone. | Eur Urol | 2019 |
| 31515154 | Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. | Lancet Oncol | 2019 |
| 31195356 | Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. | Eur J Cancer | 2019 |
| 30808776 | B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. | Clin Cancer Res | 2019 |
| 31055861 | Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancer. | BJU Int | 2019 |